engleski

Our experience with sugammadex, new antagonist of muscle relaxants

Background: Sugammadex is a new drug for neuromuscular block reversion. It is cyclic oligosaccharide, a gamma cyclodextrin with lipophylic inner coat that enables forming of stable complexes with steroidal neuromuscular blocking drugs, especially with rocuronium. In two groups of thyroid cancer patients we compared the effects of sugammadex and neostigmine for reversion of moderate block. Methods: All patients were mechanically ventilated with O2:N20 35:65 vol%. Muscle relaxation was measured using TOF-Watch. Both neostigmine with atropine and sugammadex were administered at the end of procedure. A recovery of TOF >90%, minute ventilation and the need for postoperative oxygenation were registered in the both groups. Statistical analysis was done using Chi-square and Student's t test. Results. Mean age, BMI and duration of surgery did not differ between two groups. A mean recovery time to TOF>0.9 was significantly longer in the neostigmine group as compared to the sugammadex (>15 min vs. 2.5, p<0, 001). Sugammadex provided faster recovery of TOF>0.9 and minute ventilation, enabling early neurological assessment, and shorter recovery time as compared to neostigmine.

General anesthesia; Neuromuscular blockade; antagonists; Sugammadex; Neostigmine; Thyroidectomy

nije evidentirano